Baker Bros. Advisors LP Prelude Therapeutics Inc Transaction History
Baker Bros. Advisors LP
- $8.39 Billion
- Q1 2025
A detailed history of Baker Bros. Advisors LP transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Baker Bros. Advisors LP holds 10,123,824 shares of PRLD stock, worth $9.82 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
10,123,824
Previous 10,123,824
-0.0%
Holding current value
$9.82 Million
Previous $12.9 Million
39.37%
% of portfolio
0.09%
Previous 0.14%
Shares
2 transactions
Others Institutions Holding PRLD
# of Institutions
57Shares Held
28.3MCall Options Held
23.9KPut Options Held
0-
Orbimed Advisors LLC San Diego, CA10.9MShares$10.6 Million0.26% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$1.04 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$978,9270.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD976KShares$946,8620.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny657KShares$636,9990.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $35.3M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...